Endothelial dysfunction in COVID- 19 and cognitive impairment

Close metadata

Recommended articles:

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48

Drug-induced cognitive impairment and dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):77-85

Adverse perinatal outcomes in COVID-19. Analysis of a series of clinical observations. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):86-90

Staging of COVID-19 morphological manifestations in lungs depending on disease duration. Forensic Medical Expertise. 2024;(2):28-31

Russian COVID-19 vaccines as a risk factor of myopericarditis in patients with or without previous infection. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):184-193

Exosomes’ role in intercellular interactions in different variants of lung injury in fatal cases of COVID-19. Russian Journal of Archive of Pathology. 2024;(2):22-29

Age features of immunity to SARS-CoV-2 of metropolis population in the dynamics. Russian Journal of Clinical Dermatology and Venereology. 2024;(2):118-128

Variability of death rates from respiratory diseases in the regions of the Russian Federation during the COVID-19 pandemic and the three previous years. Russian Journal of Preventive Medicine. 2024;(4):82-88

Endothelial dysfunction is an important mechanism underlying multiple organ and systems failure in COVID-19. The development of endothelial dysfunction in COVID-19 can disrupt organ perfusion and cause a procoagulant state, leading to both macro- and microvascular thrombotic events. Cognitive impairment is a common complication of COVID-19 that develop in acute and delayed periods and is not directly related to the severity of the underlying disease. Treatment of endothelial dysfunction in patients with COVID-19 should take into account the leading pathogenetic factors of its development and with the development of neurological, including cognitive, disorders should include neuroprotective drugs. One of these drugs is actovegin, which has been shown to be effective in improving endothelial function, microcirculation and cognition.

Keywords:

COVID-19

SARS-CoV-2

endothelial dysfunction

cognitive impairment

molecular mimicry

actovegin

Authors:

Martynov M.U.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency

ORCID: 0000-0003-2797-7877

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Yasamanova A.N.

Pirogov Russian National Research Medical University

Received:

08.05.2021

Accepted:

19.05.2021

List of references:

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263. https://doi.org/10.1126/science.abb2507
Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214-217. https://doi.org/10.1016/j.ijid.2020.01.050
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192. https://doi.org/10.1007/s11684-020-0754-0.
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. https://doi.org/10.1002/path.1570
Robinson FA, Mihealsick RP, Wagener BM, et al. Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. Am J Physiol Heart Circ Physiol. 2020;319(5):1059-1068. https://doi.org/10.1152/ajpheart.00681.2020;
Chen R, Wang K, Yu J, Howard D, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11:573095. https://doi.org/10.3389/fneur.2020.573095
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69. https://doi.org/10.1186/s13195-020-00640-3
Godo S, Shimokawa H. Endothelial functions. Arterioscler Thromb Vasc Biol. 2017;37(9):108-114. https://doi.org/10.1161/ATVBAHA.117.309813
Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057-1069. https://doi.org/10.7150/ijbs.7502
Chiva-Blanch G, Sala-Vila A, Crespo J, Ros E, Estruch R, Badimon L. The Mediterranean diet decreases prothrombotic microvesicle release in asymptomatic individuals at high cardiovascular risk. Clin Nutr. 2020;39(11):3377-3384. https://doi.org/10.1016/j.clnu.2020.02.027
Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981-2987. https://doi.org/10.1161/CIRCULATIONAHA.104.504340.
Oliveras A, Soler MJ, Martínez-Estrada OM, et al. Endothelial progenitor cells are reduced in refractory hypertension. J Hum Hypertens. 2008;22(3):183-190. https://doi.org/10.1038/sj.jhh.1002304
Varga Z. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
Nagashima S, Mendes MC, Camargo Martins AP, et al. Endothelial dysfunction and thrombosis in patients with COVID-19 brief report. Arterioscler Thromb Vasc Biol. 2020t;40(10):2404-2407. https://doi.org/10.1161/ATVBAHA.120.314860
Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-3044. https://doi.org/10.1093/eurheartj/ehaa623
Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol. 2021;147(1):107-111. https://doi.org/10.1016/j.jaci.2020.08.031
Petrey AC, Qeadan F, Middleton EA, Pinchuk IV, Campbell RA, Beswick EJ. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex. J Leukoc Biol. 2021;109(1):55-66. https://doi.org/10.1002/JLB.3COVA0820-410RRR
Helms J, Tacquard C, Severac F, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098. https://doi.org/10.1007/s00134-020-06062-x
Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014
Lasso G, Honig B, Shapira SD. A sweep of earth’s virome reveals host-guided viral protein structural mimicry and points to determinants of human disease. Cell Syst. 2021;12(1):82-91.e3. https://doi.org/10.1016/j.cels.2020.09.006
Yapici-Eser H, Koroglu YE, Oztop-Cakmak O, Keskin O, Gursoy A, Gursoy-Ozdemir Y. Neuropsychiatric symptoms of COVID-19 explained by SARS-CoV-2 proteins’ mimicry of human protein interactions. Front Hum Neurosci. 2021;15:656313. https://doi.org/10.3389/fnhum.2021.656313
Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92(7):699-702. https://doi.org/10.1002/jmv.25915
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13. https://doi.org/10.1016/j.trsl.2020.04.007
Lee MH, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 2021;384(5):481-483. https://doi.org/10.1056/NEJMc2033369
Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with Coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. 2020;77(11):1-7. https://doi.org/10.1001/jamaneurol.2020.2730
Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170. https://doi.org/10.1186/s13195-020-00744-w
Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. https://doi.org/10.1016/S2215-0366(20)30203-0
Varatharaj A, Thomas N, Ellul MA, et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875-882. https://doi.org/10.1016/S2215-0366(20)30287-X
Ortelli P, Ferrazzoli D, Sebastianelli L, et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci. 2021;420:117271. https://doi.org/10.1016/j.jns.2020.117271
Del Brutto OH, Wu S, Mera RM, Costa AF, Recalde BY, Issa NP. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. Eur J Neurol. 2021;10.1111/ene.14775. https://doi.org/10.1111/ene.14775
Amalakanti S, Arepalli KVR, Jillella JP. Cognitive assessment in asymptomatic COVID-19 subjects. Virusdisease. 2021;8(23): 1-4. https://doi.org/10.1007/s13337-021-00663-w
Kumar S, Veldhuis A, Malhotra T. Neuropsychiatric and cognitive sequelae of COVID-19. Front Psychol. 2021;12:577529. https://doi.org/10.3389/fpsyg.2021.577529
Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020;129:98-102. https://doi.org/10.1016/j.jpsychires.2020.06.022
Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study. medRxiv 2020.10.20.20215863. https://doi.org/10.1101/2020.10.20.20215863
Miskowiak KW, Johnsen S, Sattler SM, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48. https://doi.org/10.1016/j.euroneuro.2021.03.019
Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270. https://doi.org/10.1056/NEJMc2008597
Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020;194:105921. https://doi.org/10.1016/j.clineuro.2020.105921
Kas A, Soret M, Pyatigoskaya N, et al.; on the behalf of CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021;7(12): 1-15. https://doi.org/10.1007/s00259-020-05178-y
Ramiro S, Mostard RLM, Magro-Checa C, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143-1151. https://doi.org/10.1136/annrheumdis-2020-218479
Firan FC, Romila A, Onose G. Current synthesis and systematic review of main effects of calf blood deproteinized medicine (Actovegin) in ischemic stroke. Int J Mol Sci. 2020;21(9):3181. https://doi.org/10.3390/ijms21093181
Reichl FX, Högg C, Liu F, et al. Actovegin reduces PMA-induced inflammation on human cells. Eur J Appl Physiol. 2020;120(7):1671-1680. https://doi.org/10.1007/s00421-020-04398-2
Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate Actovegin on primary rat neurons in vitro. Neuromol Med. 2011;13:266-274. https://doi.org/10.1007/s12017-011-8157-7
Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci. 2012;322(1-2):222-227. https://doi.org/10.1016/j.jns.2012.07.069
Stelmakh A, Abrahamovych O, Cherkas A. Highly purified calf hemodialysate (Actovegin) may improve endothelial function by activation of proteasomes: A hypothesis explaining the possible mechanisms of action. Med Hypotheses. 2016;95:77-81. https://doi.org/10.1016/j.mehy.2016.09.008
Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvasc Res. 2012;84(1):86-93. https://doi.org/10.1016/j.mvr.2012.03.011
Fedorovich AA, Soboleva GN. Correction of cognitive disorders with Actovegin in patients with arterial hypertension and ischemic heart disease. Effective Pharmacotherapy. 2015;23:42-51. (In Russ.).
Tanashyan MM, Shabalina AA, Lagoda OV, et al. Multimodal approach to treatment of neurological complications of chronic brain ischemia. Terapevticheskiy Arkhiv. 2018;90(12):61-67. (In Russ.). https://doi.org/10.26442/00403660.2018.12.000010
Kovalchuk VV. The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):57-66. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-57-66

Close metadata